Anzeige
Mehr »
Freitag, 16.01.2026 - Börsentäglich über 12.000 News
Unabhängiger Analyst sieht bei dieser Goldaktie über +200% Kurspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5Y7 | ISIN: US86366E1064 | Ticker-Symbol:
NASDAQ
16.01.26 | 20:28
88,78 US-Dollar
+4,60 % +3,91
1-Jahres-Chart
STRUCTURE THERAPEUTICS INC ADR Chart 1 Jahr
5-Tage-Chart
STRUCTURE THERAPEUTICS INC ADR 5-Tage-Chart

Aktuelle News zur STRUCTURE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoStructure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why11
DoStructure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments6
06.01.Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight12
06.01.Structure Therapeutics stock gets BMO Capital's Outperform rating reaffirmed8
06.01.BMO Capital bestätigt "Outperform"-Rating für Structure Therapeutics nach Lizenzvereinbarung20
STRUCTURE THERAPEUTICS Aktie jetzt für 0€ handeln
06.01.Genentech enters $100M deal with Structure Therapeutics for GLP-1 weight-loss drug47
05.01.Structure Therapeutics Inc. - 8-K, Current Report1
22.12.25Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright3
17.12.25Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity433SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
► Artikel lesen
12.12.25Structure Therapeutics stock price target raised to $120 by Citizens4
11.12.25Structure Therapeutics closes $747.5 million public offering2
11.12.25Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs239SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
► Artikel lesen
10.12.25Structure Therapeutics prices upsized public offering, raising $650M9
10.12.25Structure Therapeutics prices upsized $650 million public offering17
10.12.25Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants210SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
► Artikel lesen
09.12.25Structure Therapeutics stock price target raised to $130 by BMO Capital6
09.12.25Structure Therapeutics: BMO Capital hebt Kursziel auf 130 US-Dollar an10
09.12.25Structure Therapeutics stock price target raised to $99 at Clear Street3
09.12.25Why Structure Therapeutics Stock Doubled and Then Some on Monday8
08.12.25Structure Therapeutics stock price target raised to $90 by Stifel6
Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2